QualityDipStocks / Health Care · Pharmaceuticals
ANI Pharmaceuticals ANIP
Outside our quality screen, so we don’t track its dips. It’s 25% below its 52-week high.
Outside our quality screen, 4% under its Market Value. No fair value estimate for now: the model’s result is too extreme to stand behind.
Worth knowing
- Down 26% from its 52-week high while revenue grew 31%
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $73.86price −4%
- Off 52-wk high
- −25%
- Risk vs market
- Lowbeta 0.26
52-week range 2% of the way from its 52-week low to its high
Price $70.67Market Value $73.86
5 bullish · 3 bearish See why
Repriced or dip?
Dip: business intact
The price is 25% below its 52-week high (Nov 4), but the business held up: revenue +30.9%, earnings per share turned to a profit, free cash flow +37.9%.
Some numbers held up (revenue +30.9%, earnings per share turned to a profit, free cash flow +37.9%), others slipped (revenue growth rate −7.8 pts, shares outstanding more shares, each owns less). The price is 25% below its 52-week high.
The price is 25% below its 52-week high, and the business changed too: revenue growth rate −7.8 pts, shares outstanding more shares, each owns less.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 10 numbers, high vs now
- Revenue, last 12 months$747M → $978M (+30.9%)held up
- Revenue growth rate+38.7% → +30.9% a year (−7.8 pts)changed
- Earnings per share, 12 monthsturned to a profitheld up
- Free cash flow, 12 months$125M → $173M (+37.9%)held up
- Operating margin2.0% → 15.4% (+13.3 pts)held up
- Shares outstanding+7.9% (more shares, each owns less)changed
- Net cash (cash minus debt)+10.0% of market cap since the highheld up
- Stock vs its sector (Health Care)stock −25%, sector median +22% since Nov 4changed
- Price fall vs business numbersprice −25%, revenue/EPS/FCF median +34% (shown, not scored)
- Valuation multipleP/FCF 15.3× at the high → 9.0× now (shown, not scored)
Business numbers as reported at the high (12 months to Jun 30, 2025) vs the latest filing (12 months to Jun 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
At the high ($94.48, Nov 4) the price assumed about 2%/yr free-cash-flow growth; at the low ($70.16, Oct 14) about −7%; today about −7%. The last 3 years delivered 41%/yr (revenue).
Dashed line: what the last 3 years delivered, 41%/yr (revenue)
| High | Low | Now | |
|---|---|---|---|
| Price | $94.48Nov 4 | $70.16Oct 14 | $70.67 |
| Implied growth | +2% | −7% | −7% |
| P/E | n/a | 14.4× | 14.5× |
| P/FCF | 15.3× | 8.9× | 9.0× |
| EV/Sales | 2.7× | 1.5× | 1.5× |
What this means: the higher the implied growth, the more the price already counts on. If today's number sits well below what the business has delivered, the market expects less than its track record.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
Estimate unreliable for ANIP: the model gives 245% above the price, more than we can stand behind (usually peak-cycle cash flow, heavy debt, or cash flows that include customer or loan balances). We’d rather show nothing than a made-up number.
What the price implies To be worth today’s price, ANIP’s free cash flow would need to shrink about 7% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much ANIP moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 2.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.26
- Volatility
- 32% vs 13% SPY
- Correlation SPY
- 0.10
- Correlation QQQ
- −0.01
How it ranks
Where ANIP stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 3 of 5 measures
- Free cash flow yield11% · free cash flow vs market capTop 10%of 1,690
- Dividends + buybacks yield1.5% · cash paid out or used to retire shares, vs market capLowest 37%of 2,227
- Revenue growth, last 12 months+31% · vs the 12 months beforeTop 15%of 2,184
- Operating margin15% · of sales kept as operating profitTop 35%of 1,549
- Return on invested capital21% · profit per dollar of capitalTop 18%of 1,001
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $73.86 · FCF value $143.55
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationFree-cash-flow yield of 11.2% (price / FCF 9.0×): $173M of free cash in the last 12 months.
GrowthSales compounded 41% a year from FY2022 to FY2025.
ValuationP/E of 14.5× vs a 28.9× median for the 161 Health Care companies we cover.
GrowthSales grew 31% to $978M over the last 12 months vs the 12 months before (SEC filings).
ValuationTrades 4.3% below its Market Value of $73.86, the average price paid since the Aug 7 filing.
Top bearish points 3 of 5
Cash returnsShare count up 7.9% in a year: existing holders are being diluted.
Cash returnsDividend yield of 0.0%, below the 1.1% median for the 65 Health Care companies we cover.
RiskReports earnings Nov 5 (consensus EPS $1.80): results can move the price sharply and reset Market Value.
All fundamentals
P/E 14.5 · FCF yield 11.2% · ROE 21%
Valuation
- P/E
- 14.5×Health Care median 28.9×
- Price / FCF
- 9.0×
- FCF yield
- 11.2%
- EV / EBITDA
- 6.3×
- Price / sales
- 1.58×
- Price / book
- 2.59×
- Market cap
- $1.5Bprice × diluted shares
- Enterprise value
- $1.5B
Growth
- Revenue, 12 months
- $978M
- Sales growth, 12 months
- +30.9%vs the 12 months before
- Sales growth, 3 yrs
- +40.8%/yrfrom FY2022
- Diluted EPS, 12 months
- $4.59
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $107M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 15.4%
- Net margin
- 10.9%
- FCF margin
- 17.7%
- Return on equity
- 21%
- Return on invested capital
- 21%
Balance sheet
- Cash & short-term inv.
- $360M
- Total debt
- $301M
- Net cash
- $59M
- Debt / equity
- 0.50×
- Interest coverage
- 4.8×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $173M
- FCF growth, 12 months
- +38%
- Dividend yield
- 0.02%$344,000 paid
- Payout ratio
- 0%
- Buybacks, 12 months
- $22M1.4% of market cap
- Share count, 1 year
- +7.9%diluted shares vs a year ago
- Stock-based comp
- $41M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From ANI Pharmaceuticals’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.1B · Sales +26%
- Free cash flow, 12 months$0.1B
- Free-cash-flow yield11.2%
- Free-cash-flow margin14%
- Gross margin60%
- Operating margin15%
- Return on invested capital13%
- Return on equity20%
- Sales growth (latest quarter vs year-ago quarter)+26%
- Net debt / EBITDA1.2×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $70.67
- 52-wk lowlowest close, 1 year$70.16−0.7%
- PriceMon Nov 2 close$70.67you are here
- Market Valueavg paid since Aug 7$73.86+4.5%
- 52-wk highhighest close, 1 year$94.48+33.7%
Momentum & 52-week range
RSI 43 · 5 days −2.7%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS$1.80
- Year-ago EPS$1.64
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
ANIP is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on ANI Pharmaceuticals in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.